Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

Amid fears of an "extremely high level of violent protests," the Brampton Triveni Mandir and Community Centre has cancelled a Life Certificate Event.

Phuket is pulling out all the stops in a monumental bid to raise a whopping 290 million baht. The cause? Building a cutting-edge cancer care centre at Vachira Phuket Hospital. This essential ...